Navigation Links
Cedars-Sinai Medical Center to Use Exosome Diagnostics Exosome RNA Biofluid Kits in Neo-Natal Setting and Cancer for Development of Personalized Medicine Diagnostics
Date:9/30/2013

NEW YORK, Sept. 30, 2013 /PRNewswire/ -- Exosome Diagnostics today announced that it has selected Cedars-Sinai Medical Center to participate in an early technology access program for use of exosome RNA biofluid extraction kits for biomarker discovery in neo-natal and other disease settings.  

"The ability to monitor patients, particularly extreme premature infants, using real-time biofluid based genetics tests, may provide critical information which is currently unavailable, said Charles F. Simmons, M.D., professor and chair of Cedars-Sinai's Department of Pediatrics. "We have been interested in exosome biology as a tool for diagnostic development, and are pleased to be selected to have access for our neonatal patients to this novel technology for biomarker discovery."

James McCullough, chief executive officer of Exosome Diagnostics said, "Partnering with clinical leaders such as Dr. Simmons and his team at Cedars-Sinai's Maxine Dunitz Children's Health Center is a high priority as we move to validate our blood RNA kits where precision monitoring of gene expressions is important to understanding effectiveness of drug therapy."

Dolores Di Vizio, M.D., Ph.D., associate professor of Surgery and an expert on blood-based biomarkers in microvesicles, who works with Vincent Funari, Ph.D., director of the Cedars-Sinai genomics core commented, "Having the opportunity to join with Dr. Simmons' initiative and apply the Exosome Diagnostics kit technology for biomarker discovery and next generation sequencing applications in clinical oncology samples will facilitate our efforts toward Precision Medicine and tailored therapy for prostate cancer. They will work together and in close collaboration with Dr. Michael Freeman, PhD, director of the Cancer Biology Program at the Samuel Oschin Comprehensive Cancer Institute."

The Exosome Center of Excellence program is designed to allow clinical centers already performing clinical research on blood based biomarkers in exosomes early access to the EXO50 exosome isolation and extraction technology, ahead of commercial launch. The goals of the early access program are to gain feedback from the clinical research community on the performance of the EXO50 kit, while generating clinically relevant data that can used immediately in the research setting.

Exosome Diagnostics rapid isolation and extraction technology produces high-quality RNA and DNA, including full length mRNA and microRNA, from patient blood (serum and plasma), for analysis by standard PCR, array, and sequencing instruments. Exosome Diagnostics proprietary technology, under development as EXO50, will enable clinicians to perform real-time biomarker analysis on patient plasma and serum samples, allowing for the advancement of personalized medicine. Exosome Diagnostics recently announced a partnership with QIAGEN for global commercialization of clinical research kits for extraction of RNA from biofluid exosomes, starting in 2014.

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The company is commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. For more information, please visit www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cedars-Sinai researchers, with stem cells and global colleagues, develop Huntingtons research tool
2. Cedars-Sinai Medical Center Recovers More Than $300 million in AR with Hyland Softwares OnBase
3. Discovery Meets Recovery in New Cedars-Sinai’s Advanced Health Sciences Pavilion Designed by HOK
4. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
5. DiaTech Life Sciences Announces Medical Advisory Board
6. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
7. Breaking Study: ICU Medicals Tego® Needlefree Connector Proves More Cost Effective Than Traditional Central Venous Catheter Locks
8. China Sky One Medical to Jointly Launch Adult Stem Cell Research Enterprise
9. Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call
10. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
11. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... DuPont Industrial Biosciences (DuPont) and Archer Daniels Midland Company ... Platts Global Energy for their platform technology to produce a revolutionary biobased ... Platts Global Energy Awards, held in New York on Thursday, Dec. 8. , ...
(Date:12/9/2016)... , Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that Biohaven has issued ... New Haven, Connecticut (PRWEB) Dec 9, 2016 ... "Biohaven") announced today that the U.S. Food and Drug ... request covering its drug candidate BHV-0223, an orally dissolving ...
(Date:12/8/2016)... Medical Incorporated ("OncoSec") (NASDAQ: ONCS ), ... announced financial results for the fiscal first quarter ... our commitment to address an unmet medical need ... with the early clinical response data presented from ... on advancing our lead program – ImmunoPulse® IL-12 ...
(Date:12/8/2016)... MOINES, Iowa , Dec. 8, 2016 Eurofins announces ... US Food and President of Eurofins Scientific Inc. (ESI). ... Division with his proven professional and entrepreneurial experience in leading international ... in the US food testing market to uphold Eurofins, status as ... ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
(Date:11/30/2016)... and WARSAW, Poland , Nov. 30, 2016 Not many ... of the most crucial aspects of recovery so we need to do it well. ... risks, including heart problems, high blood pressure, stroke, diabetes, and even cancer. ... and find a Christmas present that could help them to manage their sleep quality? ... ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
Breaking Biology News(10 mins):